阿瑞匹坦用于中国恶性肿瘤患者中吉非替尼诱导的难治性瘙痒
Aprepitant for gefitinib-induced refractory pruritus in Chinese malignancy population.
作者信息
Qin Haifeng, Wang Fang, Wang Ke, Liu Hui, Guo Rui, Zeng Zhen, Pan Xin, Fu Xiaofeng, Zhang Ting, Gao Hongjun
机构信息
Department of Pulmonary Neoplasm Internal Medicine, 307 Hospital of PLA, Beijing 100000, China.
Department of Integration Traditional Chinese and Western Medicine, Peking University Cancer Hospital, Beijing 100000, China.
出版信息
Ann Transl Med. 2019 Feb;7(3):54. doi: 10.21037/atm.2019.01.02.
Abstract
Targeted therapy is an important anti-cancer therapy in non-small cell lung cancer (NSCLC). Pruritus are the common side-effect with gefitinib, an anti-EGFR antibody and tyrosine-kinase inhibitor. We reported case reports to confirm the effects of aprepitant, a neurokinin receptor to management of refractory rash and pruritus in Chinese malignancy population. patients showed a rapid recovery from refractory pruritus, no adverse events occurred. Weekly follow-up visits showed the pruritus were stable and no further episodes was recorded.
摘要
靶向治疗是非小细胞肺癌（NSCLC）重要的抗癌治疗方法。瘙痒是抗表皮生长因子受体（EGFR）抗体及酪氨酸激酶抑制剂吉非替尼常见的副作用。我们报告了几例病例，以证实神经激肽受体拮抗剂阿瑞匹坦对中国恶性肿瘤患者难治性皮疹和瘙痒的治疗效果。患者难治性瘙痒迅速缓解，未发生不良事件。每周随访显示瘙痒症状稳定，未再出现发作。
相似文献
1
Aprepitant for gefitinib-induced refractory pruritus in Chinese malignancy population.阿瑞匹坦用于中国恶性肿瘤患者中吉非替尼诱导的难治性瘙痒
Ann Transl Med. 2019 Feb;7(3):54. doi: 10.21037/atm.2019.01.02.
2
Need for Flexible Adjustment of the Treatment Schedule for Aprepitant Administration against Erlotinib-Induced Refractory Pruritus and Skin Rush.针对厄洛替尼引起的难治性瘙痒和皮疹，需要灵活调整阿瑞匹坦给药治疗方案。
Case Rep Oncol. 2019 Jan 21;12(1):84-90. doi: 10.1159/000493256. eCollection 2019 Jan-Apr.
3
Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study.阿瑞匹坦治疗生物癌症治疗相关严重瘙痒的管理：一项初步研究。
Lancet Oncol. 2012 Oct;13(10):1020-4. doi: 10.1016/S1470-2045(12)70373-X. Epub 2012 Sep 18.
4
Aprepitant for refractory nivolumab-induced pruritus.阿瑞匹坦用于难治性纳武单抗诱导的瘙痒症。
Lung Cancer. 2017 Jul;109:58-61. doi: 10.1016/j.lungcan.2017.04.020. Epub 2017 Apr 27.
5
Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study.在难治性非小细胞肺癌（NSCLC）患者中，使用IgG1单克隆抗体西妥昔单抗和酪氨酸激酶抑制剂吉非替尼双重抑制表皮生长因子受体：一项I期研究。
J Thorac Oncol. 2008 Mar;3(3):258-64. doi: 10.1097/JTO.0b013e3181653d1b.
6
Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature.阿瑞匹坦治疗难治性皮肤T细胞淋巴瘤相关瘙痒：4例病例及文献综述
BMC Cancer. 2017 Mar 16;17(1):200. doi: 10.1186/s12885-017-3194-8.
7
Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC).吉非替尼（一种表皮生长因子受体酪氨酸激酶抑制剂，EGFR-TKI）与塞来昔布（一种环氧化酶-2，COX-2抑制剂）用于铂类难治性非小细胞肺癌（NSCLC）患者的II期研究。
J Thorac Oncol. 2007 Apr;2(4):299-305. doi: 10.1097/01.JTO.0000263712.61697.69.
8
Aprepitant for the Treatment of Chronic Refractory Pruritus.阿瑞匹坦治疗慢性难治性瘙痒症。
Biomed Res Int. 2017;2017:4790810. doi: 10.1155/2017/4790810. Epub 2017 Sep 19.
9
10
First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations.表皮生长因子受体（EGFR）突变的老年（年龄≥75岁）非小细胞肺癌患者的一线吉非替尼治疗
Cancer Chemother Pharmacol. 2015 Oct;76(4):761-9. doi: 10.1007/s00280-015-2841-5. Epub 2015 Aug 8.
引用本文的文献
1
Neurokinin-1 antagonist orvepitant for EGFRI-induced pruritus in patients with cancer: a randomised, placebo-controlled phase II trial.神经激肽-1 拮抗剂奥那司坦治疗癌症患者表皮生长因子受体抑制剂相关瘙痒：一项随机、安慰剂对照的 II 期试验。
BMJ Open. 2020 Feb 6;10(2):e030114. doi: 10.1136/bmjopen-2019-030114.
本文引用的文献
1
Aprepitant for the Treatment of Chronic Refractory Pruritus.阿瑞匹坦治疗慢性难治性瘙痒症。
Biomed Res Int. 2017;2017:4790810. doi: 10.1155/2017/4790810. Epub 2017 Sep 19.
2
Risk of pruritus in cancer patients treated with biological therapies: A systematic review and meta-analysis of clinical trials.接受生物疗法治疗的癌症患者发生瘙痒的风险：一项对临床试验的系统评价和荟萃分析。
Crit Rev Oncol Hematol. 2015 Nov;96(2):206-19. doi: 10.1016/j.critrevonc.2015.05.007. Epub 2015 Jun 10.
3
New insights into the mechanisms of itch: are pain and itch controlled by distinct mechanisms?瘙痒机制的新见解：疼痛和瘙痒是否由不同的机制控制？
Pflugers Arch. 2013 Dec;465(12):1671-85. doi: 10.1007/s00424-013-1284-2. Epub 2013 May 1.
4
Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study.阿瑞匹坦治疗生物癌症治疗相关严重瘙痒的管理：一项初步研究。
Lancet Oncol. 2012 Oct;13(10):1020-4. doi: 10.1016/S1470-2045(12)70373-X. Epub 2012 Sep 18.
5
Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.EGFR 抑制剂相关性皮肤毒性的预防和治疗临床实践指南。
Support Care Cancer. 2011 Aug;19(8):1079-95. doi: 10.1007/s00520-011-1197-6. Epub 2011 Jun 1.
6
More on aprepitant for erlotinib-induced pruritus.关于阿瑞匹坦治疗厄洛替尼引起的瘙痒的更多信息。
N Engl J Med. 2011 Feb 3;364(5):486-7. doi: 10.1056/NEJMc1013027.
7
Dermatologic toxicities of targeted anticancer therapies.靶向抗癌疗法的皮肤毒性
J Support Oncol. 2010 Jul-Aug;8(4):149-61.
8
How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors?MESTT 与 CTCAE 量表在评估与口服酪氨酸激酶抑制剂相关的皮肤毒性方面的相关性如何？
Support Care Cancer. 2011 Oct;19(10):1667-74. doi: 10.1007/s00520-010-0999-2. Epub 2010 Sep 5.
9
Preliminary evidence for a role of mast cells in epidermal growth factor receptor inhibitor-induced pruritus.肥大细胞在表皮生长因子受体抑制剂诱导的瘙痒中作用的初步证据。
J Am Acad Dermatol. 2010 Jul;63(1):163-5. doi: 10.1016/j.jaad.2009.09.023.
10
Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy.以神经激肽受体 1 为靶点的阿瑞匹坦：一种新的止痒策略。
PLoS One. 2010 Jun 4;5(6):e10968. doi: 10.1371/journal.pone.0010968.
Zotero 插件